FGF21 and metabolic dysfunction-associated steatohepatitis: One study has demonstrated that activation of hepatic FXR improves the histological features of NASH by inducing the expression of fibroblast growth factor 21 (FGF21), a strong regulator of lipocalin, via the induction of upregulation of lipocalin expression (Cyphert et al., 2012), thereby improving insulin resistance and hepatic fat accumulation (Liu et al., 2020).